Companies Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Source: General Cancer News Articles Provided by Cancer Compass

  • Share/Bookmark

Leave a Reply